Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 5,921 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mouth Disease Clear all
Completed Phase 2 Interventional

Dexamethasone to Treat Oral Lichen Planus

NCT00111072
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
dexamethasone 0.01% solution
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 3 Interventional

A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

NCT00002339
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System

NCT02722967
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
Interventions
Aripiprazole + IEM (Ingestible Event Marker)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Granada Hills, California • Rochester, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 31, 2026, 6:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Study of Oral Endosseous Titanium Implants in Edentulous Subjects

NCT00001211
View directory record Official record
Conditions
Ectodermal Dysplasia, Jaw, Edentulous
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1986 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 1 Interventional

Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis

NCT00440492
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
PLA-695
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2007 · Synced Oct 31, 2026, 6:35 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)

NCT06941844
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, DT120
Other · Drug
Lead sponsor
Definium Therapeutics US, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
22
States / cities
Little Rock, Arkansas • La Jolla, California • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma

NCT00743509
View directory record Official record
Conditions
Osteosarcoma
Interventions
Cyclophosphamide and Sirolimus
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
16 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 4 Interventional

PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia

NCT02598453
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
60
States / cities
Montgomery, Alabama • Lake Havasu City, Arizona • Paradise Valley, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

NCT02971007
View directory record Official record
Conditions
Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Interventions
Oral Encochleated Amphotericin B (CAMB), Fluconazole
Drug
Lead sponsor
Matinas BioPharma Nanotechnologies, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

NCT02336451
View directory record Official record
Conditions
ALK-positive Non-small Cell Lung Cancer
Interventions
Ceritinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Los Angeles, California • Stanford, California • South Bend, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Not applicable Interventional

Pulsed Dye Laser in Treating Patients With Post Radiation Dysphonia

NCT02198131
View directory record Official record
Conditions
Oral Complications of Radiation Therapy, Stage I Laryngeal Cancer, Stage II Laryngeal Cancer
Interventions
laser therapy, questionnaire administration
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 31, 2026, 6:35 AM EDT
Recruiting Not applicable Interventional

Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders

NCT07180537
View directory record Official record
Conditions
Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Psoriatic Arthritis, Anxiety Disorders, Depressive Disorders, Moderate Depression, Moderate Anxiety
Interventions
Creating Health Online Course, Delayed access to Creating Health Online Course
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers

NCT04588129
View directory record Official record
Conditions
Schizophrenia
Interventions
LB-102
Drug
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 2 Interventional

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

NCT00979251
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir Phosphate, ADS-8902
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
San Francisco, California • Hollywood, Florida • Miramar, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 in Healthy Females

NCT01373931
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
LY2216684, Ortho Cyclen, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure

NCT02606253
View directory record Official record
Conditions
Heart Failure
Interventions
tolvaptan, Chlorothiazide, Metolazone
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis

NCT02965781
View directory record Official record
Conditions
Herpes Labialis, Cold Sore
Interventions
SADBE, Placebo
Drug · Other
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Redwood City, California • Doral, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 31, 2026, 6:35 AM EDT
Terminated Phase 1 Interventional

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT04570631
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Eftozanermin alfa, Bortezomib, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Atlanta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study for an Oral Contraceptive Containing Folate

NCT00468481
View directory record Official record
Conditions
Neural Tube Defects, Contraception, Oral Contraceptives (OC)
Interventions
Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Anaheim, California • San Diego, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

IBUPAP Study for Pain Management in Children

NCT03088800
View directory record Official record
Conditions
Pain Management
Interventions
Ibuprofen, APAP
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
3 Years to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2

NCT01976936
View directory record Official record
Conditions
Stroke, Rhabdomyolysis, Jaundice
Interventions
Low Dose Lovastatin, Placebo, High Dose Lovastatin
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

NCT01240967
View directory record Official record
Conditions
Healthy Volunteers, Patients, Pharmacokinetics, Renal Impairment
Interventions
TC-5214
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Results available

Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

NCT01318902
View directory record Official record
Conditions
Light-Chain Amyloidosis
Interventions
Ixazomib, Dexamethasone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

NCT02576639
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CNP520, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Glendale, California • Long Beach, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 31, 2026, 6:35 AM EDT